for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSPC Pharmaceutical Group Ltd

1093.HK

Latest Trade

7.37HKD

Change

-0.20(-2.64%)

Volume

109,662,966

Today's Range

7.34

 - 

7.60

52 Week Range

6.83

 - 

11.16

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Cspc Pharmaceutical Says Sysa1801 Independently Developed By Unit Granted Orphan-Drug Designation By U.S. FDA

Nov 24 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::CSPC PHARMACEUTICAL- SYSA1801 INDEPENDENTLY DEVELOPED BY UNIT GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA.

CSPC Pharmaceutical Says Jiang Hao Appointed Executive Director

Nov 23 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::JIANG HAO APPOINTED EXECUTIVE DIRECTOR.

CSPC Pharmaceutical Posts 9-Month Profit Attributable RMB3.52 Billion

Nov 23 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::9-MONTH TOTAL REVENUE RMB 19.22 BILLION VERSUS RMB 16.76 BILLION.9-MONTH PROFIT ATTRIBUTABLE RMB3.52 BILLION VERSUS RMB2.81 BILLION.

CSPC Pharmaceutical Says "Syha1813 Oral Solutions" Obtains Clinical Trial Approval

Nov 3 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::"SYHA1813 ORAL SOLUTIONS" OBTAINS CLINICAL TRIAL APPROVAL.

CSPC Pharmaceutical Says 9-Mth Revenue For CSPC Innovation Pharmaceutical RMB1.03 Bln

Oct 22 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::9-MONTH REVENUE FOR CSPC INNOVATION PHARMACEUTICAL RMB1.03 BILLION, UP 7.58%.9-MONTH NET PROFIT ATTRIBUTABLE FOR CSPC INNOVATION PHARMACEUTICAL RMB 257.2 MILLION, UP 20.56%.

CSPC Pharmaceutical Says "Docetaxel For Injection (Albumin-Bound)" Gets Clinical Trial Approval In U.S

Sept 17 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::"DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL IN U.S.

Cspc Pharmaceutical Says Almb-0168 Obtains Clinical Trial Approval For Investigational New Drug In China

Sept 15 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::ALMB-0168 OBTAINS CLINICAL TRIAL APPROVAL FOR NVESTIGATIONAL NEW DRUG IN CHINA.

CSPC Pharmaceutical HY Profit Attributable RMB2.31 Bln

Aug 26 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::HY PROFIT ATTRIBUTABLE RMB2.31 BILLION VERSUS RMB1.88 BILLION.HY TOTAL REVENUE RMB12.59 BILLION VERSUS RMB11.18 BILLION.INTERIM DIVIDEND PER SHARE HK6 CENTS.

CSPC Pharmaceutical Announces Acceptance Of NDA

Aug 25 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::NDA FOR UNIT'S MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION ACCEPTED BY CENTER FOR DRUG EVALUATION OF NMPA.

CSPC Pharmaceutical Says Unit's "Syha1815 Tablets" Obtained Approval By NMPA

Aug 24 (Reuters) - CSPC Pharmaceutical Group Ltd <1093.HK>::UNIT'S "SYHA1815 TABLETS" OBTAINED APPROVAL BY NMPA TO CONDUCT CLINICAL TRIALS IN CHINA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up